Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VITARINE'S INITIAL PUBLIC OFFERING IS POSTPONED

Executive Summary

VITARINE'S INITIAL PUBLIC OFFERING IS POSTPONED pending completion of FDA's inspection of the company's St. Croix, Virgin Islands manufacturing facility. "The postponement was requested by the company in order to enable senior management to clarify issues that have arisen in connection with the accuracy of certain documents relating to a product application at its St. Croix plant," Vitarine said in a recent statement. Vitarine's facility in St. Croix is under active investigation by FDA, according to the agency. Reportedly, the company does not have any generic antibiotic applications pending at FDA that could be held up by the investigation. According to Vitarine's recent prospectus, a Virgin Islands subsidiary "owns two buildings aggregating approximately 20,000 square feet located in St. Croix." The filing notes that "since April 1987, one building has been used solely for the purpose of manufacturing cephalosporins [and] since 1987, the company has spent approximately $123,000 in improving the second building to be available for the manufacture of other products." The document adds that production of the "other products" began in September 1988. Vitarine hopes to raise between $18.7 mil. and $22.1 mil. from the 1.7 mil. share initial public offering, based on an offering price of between $11 and $13 a share. Proceeds from the offering will go towards eliminating debt taken on during Vitarine's acquisition of six regional generic drug distributors last year. The distributors were purchased at a total price of $53.4 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel